Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jun 09 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced the commencement of the Phase IV EVIDENCES-XI trial for Saroglitazar Mg in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and comorbidities. This study is expected to generate significant Real World Evidence to support clinical guidelines for managing NAFLD and NASH. The press release emphasizes the importance of this trial in addressing unmet healthcare needs in these conditions.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 09, 2023, titled "Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in Non-Alcoholic Fatty Liver Disease (NAFLD) patients with comorbidities".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases